Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib

The vast majority of chronic myeloid leukemia patients express a BCR-ABL1 fusion gene mRNA encoding a 210 kDa tyrosine kinase which promotes leukemic transformation. A possible differential impact of the corresponding BCR-ABL1 transcript variants e13a2 (“b2a2”) and e14a2 (“b3a2”) on disease phenotyp...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Haematologica
Main Authors: Hanfstein, Benjamin, Lauseker, Michael, Hehlmann, Rüdiger, Saussele, Susanne, Erben, Philipp, Dietz, Christian, Fabarius, Alice, Proetel, Ulrike, Schnittger, Susanne, Haferlach, Claudia, Krause, Stefan W., Schubert, Jörg, Einsele, Hermann, Hänel, Mathias, Dengler, Jolanta, Falge, Christiane, Kanz, Lothar, Neubauer, Andreas, Kneba, Michael, Stegelmann, Frank, Pfreundschuh, Michael, Waller, Cornelius F., Spiekermann, Karsten, Baerlocher, Gabriela M., Pfirrmann, Markus, Hasford, Joerg, Hofmann, Wolf-Karsten, Hochhaus, Andreas, Müller, Martin C.
Formato: Artigo
Idioma:Inglês
Publicado em: Ferrata Storti Foundation 2014
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4562532/
https://ncbi.nlm.nih.gov/pubmed/24837466
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2013.096537
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados